Cannabis Use, Neurobiology, Psychology, and Treatment

<p>Preface</p> <p>I. Setting the scene and introductory chapters</p> <p>1. Metabolomics of the cannabis plant<br>Mickel Hiebert-Giesbrecht, Claudia Torres-Calzada and David Scott Wishart</p> <p>2. The roots of Cannabis sativa: chemical and pharmacological profile<br>L A. Rolim</p> <p>3. Cannabis related compounds in beverages and food<br>Ilaria Di Marco Pisciottano</p> <p>4. The impact of prenatal cannabis exposure: an overview<br>Natalia Kleinhans</p> <p>5. Cannabis Genotoxicity and Cancer Incidence: Highly Concordant Synthesis of European and USA Datasets<br>Albert Stuart Reece and Gary K. Hulse</p> <p>6. Cannabis Genotoxicity and Cancer Incidence: A Highly Concordant Synthesis of European and USA Datasets<br>Albert Stuart Reece and Gary K. Hulse</p> <p>7. Cannabis, Cognitive impairment and Car Crash risk <br>U.W. Preuss</p> <p>II. Cannabis usage</p> <p>8. Recreational cannabis use: a French perspective of adverse effects<br>Emilie Bouquet, Emilie Jouanjus and Maryse Lapeyre-Mestre</p> <p>9. Acute and chronic impact of cannabis on human cognition<br>Justin Matheson and Bernard Le Foll</p> <p>10. Polydrug users, use of cannabidiol (CBD) and abuse potential/Polydrug users, use of cannabinoids and abuse potential<br>Kerri Alexandra Schoedel</p> <p>11. Cannabis stigmas: a narrative of features<br>Matt Reid</p> <p>12. Alterations of THC and CBD ratios and impact on cognition<br>Erica Zamberletti</p> <p>13. When cannabis is used for medicinal purposes: a focus on back pain<br>R. L. Price III</p> <p>III. Pharmacological and Physiological Aspects</p> <p>14. Cannabis, cannabinoids and receptor responses<br>Yi Yang, Roya Derwish and Lakshmi P. Kotra</p> <p>15. Cannabidiol (CBD): abuse potential and withdrawal<br>Kenneth W. Sommerville and Beatrice Setnik</p> <p>16. 4,5- Dihydro-1H-pyrazole/3,4-Diarylpyrazoline class of cannabinoid-1 (CB1R) receptor antagonists and their potential in medicinal applications <br>Malliga R. Iyer</p> <p>IV. Neurobiology of cannabis</p> <p>17. Neurobiology of cannabis<br>Rohit Goyal and Deepak Kumar</p> <p>18. The kynurenine pathway, neurobiology and cannabis misuse: a new narrative<br>Nuria Morales-Puerto and Esther O'Shea</p> <p>19. Central nervous system cancers and use of cannabis and related products: an updated narrative<br>J. Eduardo Rodriguez Almaraz and Nicholas Butowski</p> <p>20. Chronic cannabis users: links with glutamate and resting state connectivity<br>S.D. Newman</p> <p>21. Brain metabolic responses to cannabis use in people with multiple sclerosis: Insights from [18F]-FDG positron emission tomography and functional MRI<br>Thorsten Rudroff</p> <p>22. Genetic Variation and Acute Responses to Cannabis <br>Bernard Le Foll, Zoe Bourgault and Justin Matheson</p> <p>23. Cell Signaling of the CB1 Cannabinoid Receptor via beta-arrestins, Cannabinoid Receptor Interacting Protein (CRIP1a) and other regulatory proteins<br>Allyn C. Howlett</p> <p>24. Cannabis and impact on memory: from in utero to adults<br>Jennifer Willford, Meaghan Hazelet, Mohamad Khalaifa, Natacha DeGenna and Gale A. Richardson</p> <p>25. Central CB1 receptors and age-related changes: investigating the effects of DELTA-9-tetrahydrocannabinol<br>Brett C. Ginsburg and Hanana AlTfaili</p> <p>26. Alcohol, cannabis and visual memory<br>Concepcion Vinader-Caerols</p> <p>V. Neurobiology of cannabinoids</p> <p>27. The role of Delta-FosB in the plasticity of the cannabinoid system<br>Arturo Venebra-Munoz and Sara Mejía-Chávez</p> <p>28. Functional profile of synthetic cannabinoid receptor agonists: exploring cannabinoid and non-cannabinoid targets <br>Shivani Sachdev, Marina Santiago and Chris Bladen</p> <p>29. Linking the G protein-coupled orphan receptor GPR55 to the cannabinoid receptors (CB1 and CB2): a new narrative<br>Paula Morales, Raquel Guerrero-Alba and B.A. Marichal-Cancino</p> <p>30. Proteomic analysis of cannabinoids in human oligodendrocytes<br>Valéria Almeida</p> <p>31. Cannabinoids and endocannabinoid signaling at the basal forebrain cholinergic system<br>Rafael Rodriguez</p> <p>32. Cannabidiol (The major non-psychotropic cannabinoid in the cannabis plant) and the PI3K/Akt pathway in the CNS<br>Nadja Schroder</p> <p>33. Effects of cannabidiol and other phytocannabinoids on ion channels<br>Murat Oz, Keun-Hang Susan Yang, Mohamed Mahgoub, Georg Petroianu and Dietrich Lorke</p> <p>34. Cannabis, neurodevelopment and the "two-hit hypothesis"<br>Elisa Guma, Lani Cupo and Mallar Chakravarty</p> <p>VI. New and synthetic cannabinoids</p> <p>35. Impact of tetrahydrocannabinol (THC ) and synthetic "spice"cannabinoids on nicotine use and abuse<br>Christie Dawn Fowler and Angeline Dukes</p> <p>36. Synthetic cannabinoids: how do they compare to DELTA9-tetrahydrocannabinol: neurological effects and beyond<br>Chris S. Breivogel</p> <p>VII. Biomarkers, analysis and screening</p> <p>37. The DSM-5 criteria of cannabis use disorder: methods and applications<br>Mahadev Sen, Siddharth Sarkar and Yesh Singh</p> <p>38. Cannabis and clinical high risk for psychosis: monitoring and smartphones<br>Jean Addington</p> <p>VIII. Impact on non-neurological systems</p> <p>39. The impact of cannabis and cannabinoids on the skin<br>Jane M. Grant-Kels</p> <p>40. Cannabis consumption in reproduction and teratogenicity<br>Susana Sa and B.M. Fonseca</p> <p>41. Cannabis compounds and putative cytotoxicity: profile of cancer cells<br>Hadar Peeri and Hinanit Koltai</p> <p>IX. Treatments, strategies and resources</p> <p>42. Motivational Interviewing for Cannabis Use Disorders: a narrative review from research to practice<br>Hugo López-Pelayo, Maria Teresa Pons-Cabrera, Clara Oliveras Salvà and Pablo Rodrigo Guzmán Cortez</p> <p>43. An Overview of Current Pharmacologic Interventions for Management of Cannabis Withdrawal and the Evidence for Their Use<br>David Wolinsky</p> <p>44. Managing cannabinoid hyperemesis syndrome in paediatrics: A new narrative review<br>Justin P. Reinert</p> <p>45. Gabapentinoids for the Treatment of Cannabis Use Disorder: A Focus on Human Laboratory Research<br>Joshua A. Lile</p> <p>46. Treating psychosis in users of synthetic cannabinoids<br>T. Klimenko and Svetlana Shakhova</p> <p>X. Resources</p> <p>47. Cannabis and Web based Resources<br>Rajkumar Rajendram</p>